Neoleukin Therapeutics (NLTX) Competitors $19.98 -0.01 (-0.05%) As of 08/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. GYRE, TNGX, NRIX, PROK, ABUS, GHRS, TBPH, TYRA, KALV, and KURAShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Gyre Therapeutics (GYRE), Tango Therapeutics (TNGX), Nurix Therapeutics (NRIX), ProKidney (PROK), Arbutus Biopharma (ABUS), GH Research (GHRS), Theravance Biopharma (TBPH), Tyra Biosciences (TYRA), KalVista Pharmaceuticals (KALV), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors Gyre Therapeutics Tango Therapeutics Nurix Therapeutics ProKidney Arbutus Biopharma GH Research Theravance Biopharma Tyra Biosciences KalVista Pharmaceuticals Kura Oncology Neoleukin Therapeutics (NASDAQ:NLTX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment. Do institutionals & insiders hold more shares of NLTX or GYRE? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor NLTX or GYRE? In the previous week, Gyre Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Gyre Therapeutics and 0 mentions for Neoleukin Therapeutics. Gyre Therapeutics' average media sentiment score of 0.86 beat Neoleukin Therapeutics' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Gyre Therapeutics Positive Is NLTX or GYRE more profitable? Gyre Therapeutics has a net margin of 4.08% compared to Neoleukin Therapeutics' net margin of 0.00%. Gyre Therapeutics' return on equity of 7.67% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Gyre Therapeutics 4.08%7.67%6.19% Which has preferable earnings & valuation, NLTX or GYRE? Gyre Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.42Gyre Therapeutics$105.76M7.07$12.09M$0.01776.00 Which has more risk and volatility, NLTX or GYRE? Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Do analysts recommend NLTX or GYRE? Gyre Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 131.96%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGyre Therapeutics beats Neoleukin Therapeutics on 14 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.77M$842.59M$5.74B$9.75BDividend YieldN/A4.84%3.95%4.07%P/E Ratio-6.421.1530.3326.09Price / SalesN/A26.29462.11120.66Price / CashN/A19.5637.7259.08Price / Book1.806.749.776.67Net Income-$57.56M-$4.20M$3.27B$265.43M7 Day Performance-2.30%3.84%3.95%3.11%1 Month Performance-12.06%2.35%3.81%0.39%1 Year Performance-45.63%12.14%31.26%18.52% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$19.98-0.1%N/A-42.8%$187.77MN/A-6.4290GYREGyre Therapeutics1.1279 of 5 stars$7.76-5.4%$18.00+132.0%-36.1%$747.37M$105.76M776.7840Analyst ForecastTNGXTango Therapeutics1.6114 of 5 stars$6.68-0.6%$10.50+57.2%-41.9%$743.22M$42.07M-5.0290Insider TradeGap DownNRIXNurix Therapeutics2.6098 of 5 stars$9.53-1.4%$28.87+202.9%-59.7%$728.56M$88.38M-3.65300News CoveragePositive NewsPROKProKidney3.7187 of 5 stars$2.38+1.3%$6.25+162.6%-1.7%$700.39M$80K-4.183ABUSArbutus Biopharma2.6892 of 5 stars$3.65+4.3%$5.50+50.7%-10.0%$699.71M$6.17M-12.5990Positive NewsHigh Trading VolumeGHRSGH Research1.4219 of 5 stars$13.39+1.6%$32.00+139.0%+14.8%$696.66MN/A-18.0910Upcoming EarningsHigh Trading VolumeTBPHTheravance Biopharma2.1227 of 5 stars$13.80flat$21.33+54.6%+70.6%$694.97M$64.38M57.50110News CoverageTYRATyra Biosciences2.2204 of 5 stars$12.64+5.3%$30.83+143.9%-45.6%$673.71MN/A-7.1020KALVKalVista Pharmaceuticals3.794 of 5 stars$13.16+1.3%$26.29+99.7%+2.9%$662.47MN/A-3.57100News CoverageInsider TradeKURAKura Oncology3.9454 of 5 stars$7.58-0.9%$24.10+217.9%-62.1%$657.94M$53.88M-3.35130Positive News Related Companies and Tools Related Companies Gyre Therapeutics Alternatives Tango Therapeutics Alternatives Nurix Therapeutics Alternatives ProKidney Alternatives Arbutus Biopharma Alternatives GH Research Alternatives Theravance Biopharma Alternatives Tyra Biosciences Alternatives KalVista Pharmaceuticals Alternatives Kura Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access